JP5927782B2 - 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途 - Google Patents

石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途 Download PDF

Info

Publication number
JP5927782B2
JP5927782B2 JP2011123853A JP2011123853A JP5927782B2 JP 5927782 B2 JP5927782 B2 JP 5927782B2 JP 2011123853 A JP2011123853 A JP 2011123853A JP 2011123853 A JP2011123853 A JP 2011123853A JP 5927782 B2 JP5927782 B2 JP 5927782B2
Authority
JP
Japan
Prior art keywords
calcification
fgf23
kle
klotho
hard tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011123853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012021974A (ja
Inventor
裕二 吉子
裕二 吉子
朋子 南崎
朋子 南崎
広陽 吉岡
広陽 吉岡
憲彦 前田
憲彦 前田
克之 香西
克之 香西
和晃 渡邉
和晃 渡邉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAFFINEE INTERNATIONAL CO.,LTD.
Hiroshima University NUC
Original Assignee
RAFFINEE INTERNATIONAL CO.,LTD.
Hiroshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RAFFINEE INTERNATIONAL CO.,LTD., Hiroshima University NUC filed Critical RAFFINEE INTERNATIONAL CO.,LTD.
Priority to JP2011123853A priority Critical patent/JP5927782B2/ja
Publication of JP2012021974A publication Critical patent/JP2012021974A/ja
Application granted granted Critical
Publication of JP5927782B2 publication Critical patent/JP5927782B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
JP2011123853A 2010-06-15 2011-06-01 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途 Active JP5927782B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011123853A JP5927782B2 (ja) 2010-06-15 2011-06-01 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010136637 2010-06-15
JP2010136637 2010-06-15
JP2011123853A JP5927782B2 (ja) 2010-06-15 2011-06-01 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途

Publications (2)

Publication Number Publication Date
JP2012021974A JP2012021974A (ja) 2012-02-02
JP5927782B2 true JP5927782B2 (ja) 2016-06-01

Family

ID=45348063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011123853A Active JP5927782B2 (ja) 2010-06-15 2011-06-01 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途

Country Status (2)

Country Link
JP (1) JP5927782B2 (fr)
WO (1) WO2011158655A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3724230A4 (fr) * 2017-12-13 2022-01-19 Yale University Compositions et méthodes de traitement ou de prévention de maladies liées au fgf endocrinien
CN109030835B (zh) * 2018-09-06 2021-06-22 江苏省人民医院（南京医科大学第一附属医院） 一种分析Rab8调节Klotho表达在非小细胞肺癌中的作用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
JP2006158339A (ja) * 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
JP2008017790A (ja) * 2006-07-14 2008-01-31 Hiroshima Univ 石灰化調節剤及びそのスクリーニング法
JP5187837B2 (ja) * 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
WO2009133905A1 (fr) * 2008-04-28 2009-11-05 協和発酵キリン株式会社 Peptide capable d’inhiber l’activité du facteur de croissance des fibroblastes 23 humain (fgf-23 humain), et composition pharmaceutique comprenant celui-ci

Also Published As

Publication number Publication date
WO2011158655A1 (fr) 2011-12-22
JP2012021974A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
Yoshiko et al. Mineralized tissue cells are a principal source of FGF23
EP2711023B1 (fr) Promoteur d'ostéogenèse
Kémoun et al. Human dental follicle cells acquire cementoblast features under stimulation by BMP-2/-7 and enamel matrix derivatives (EMD) in vitro
Morvan et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass
Shweke et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-β activation and cell infiltration
Dejaeger et al. Integrin‐linked kinase regulates bone formation by controlling cytoskeletal organization and modulating BMP and Wnt signaling in osteoprogenitors
Ito et al. Sclerostin directly stimulates osteocyte synthesis of fibroblast growth factor-23
JP6565121B2 (ja) 代謝障害を治療する方法
Liu et al. Alkaline phosphatase controls lineage switching of mesenchymal stem cells by regulating the LRP6/GSK3β complex in hypophosphatasia
Hwang et al. Deletion of Orai1 alters expression of multiple genes during osteoclast and osteoblast maturation
Nozawa et al. Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass
Ouyang et al. DEPTOR exacerbates bone–fat imbalance in osteoporosis by transcriptionally modulating BMSC differentiation
Hayashibara et al. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions
JP5927782B2 (ja) 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途
JP2008017790A (ja) 石灰化調節剤及びそのスクリーニング法
Anginot et al. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis
WO2007068003A2 (fr) Compositions et procedes de modulation de la differenciation de cellules osteoblastes et de generation osseuse par hif-1a
Berry et al. JunB as a downstream mediator of PTHrP actions in cementoblasts
JP5950380B2 (ja) リン酸化ペプチドならびに硬組織および／または異所性石灰化抑制剤
JP5808904B2 (ja) プロヒビチン２とＰＧＣ１αとの結合を用いた脂肪分化調節剤
Gamberale Cellular and molecular characterization of the infiltrating polarized macrophages during the onset of heterotopic ossification in a mouse model of Fibrodysplasia Ossificans Progressiva (FOP).
Canonical Dkk Proteins Control Osteoblast Function and Bone Formation both In
Mbimba Jr Traficking Protein Particle Complex (TRAPPC)-9: A Novel Protein Regulator of NF-kB Mediated Bone Formation and Resorption
Chen Calcium mediated differentiation of ameloblasts via the calcium sensing receptor
Liu Functional analysis of the lipid phosphatase, Inpp4b, in osteoblast physiology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160411

R150 Certificate of patent or registration of utility model

Ref document number: 5927782

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250